Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Sutro Biopharma, Inc.NASDAQ: STRO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $103.08M rose 156074.2% year over year, ahead of the +5.6% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -90.3% a year.

Context

  • Financing cash flow amounted to 0.0% of revenue in FY2025, down 151.6 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +156074.2% holds above the trailing-twelve-month pace of +5.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$103.08M+161154.7% QoQ
Last fiscal yearDec 2025
$44K-100.0% YoY
LTMMar 2026
$103.05M+5.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+156074.2%——
1 year-100.0%——
3-year CAGR-90.3%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
44K USD
Year-over-year change
-100.0%
4-year CAGR
-65.9%

Financing Cash Flow vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.6% is the 5th highest of 8, against a peer median of +305.0%.
  • Financing cash flow amounts to 103.5% of revenue for STRO, versus a peer median of 4375.6%.
STRO Competitors
Financing Cash Flow for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$108.9M USD+27468.4%+189.0%—
STROSutro Biopharma, Inc.LTM Mar 2026$103.05M USD+5.6%-90.3%103.5%
DTILPrecision BioSciences, Inc.LTM Mar 2026$85.22M USD+305.0%+0.1%189.1%
STTKShattuck Labs, Inc.LTM Mar 2026$70.43M USD+7606.1%+538.8%7043.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$52.42M USD—+132.0%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$32.12M USD-1858.1%——
IFRXInflaRx N.V.LTM Mar 2026€6.23M EUR-77.3%+154.7%21245.3%
CNTBConnect Biopharma Holdings LimitedFY2025$1.09M USD+381.5%—1707.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$342K USD-100.2%——
Peer median (excluding STRO) —+305.0%+154.7%4375.6%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Depreciation & Amortization4.84M5.69M6.82M7.22M7.32M
Deferred Income Tax7.24M0000
Stock-Based Compensation23.24M26.3M24.91M24.69M14.01M
Change in Working Capital(17.62M)104.41M(34.38M)8.9M(50.4M)
Accounts Receivables(6.9M)5.34M(28.96M)27.46M4.64M
Inventory(4.55M)0000
Accounts Payables6.43M(1.23M)4.81M706K(2.47M)
Other Working Capital(12.61M)100.29M(10.23M)(19.27M)(52.57M)
Other Non-Cash Items6.16M(13.65M)(2.17M)(4.88M)42.92M
Operating Cash Flow(81.68M)3.55M(111.62M)(191.54M)(177.23M)
Capital Expenditures(15.32M)(7.86M)(4.32M)(3.1M)(1.7M)
Acquisitions (Net)028.74M000
Purchases of Investments(248.73M)(216.67M)(460.3M)(461.52M)(264.95M)
Sales of Investments166.73M189.5M460.69M683.13M311.66M
Other Investing Activities9K(28.73M)000
Investing Cash Flow(97.32M)(35.02M)(3.92M)218.51M45.01M
Debt Repayment0(9.38M)(12.5M)(4.08M)0
Common Stock Issued056.27M11.97M96.53M376K
Common Stock Repurchased(7K)0000
Dividends Paid00000
Other Financing Activities4.25M1.42M138.08M1.61M(332K)
Financing Cash Flow3.26M48.31M137.55M94.05M44K
Effect of Forex Changes00000
Net Change in Cash(175.74M)16.84M22.01M121.02M(132.17M)
Free Cash Flow(97M)(4.31M)(115.93M)(194.64M)(178.93M)

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.